Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence-Reference-Cited by-同舟云学术

Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence

Published:2008-12 Issue:6 Volume:146 Page:802-812.e1
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Kempen John H.,Gangaputra Sapna,Daniel Ebenezer,Levy-Clarke Grace A.,Nussenblatt Robert B.,Rosenbaum James T.,Suhler Eric B.,Thorne Jennifer E.,Foster C. Stephen,Jabs Douglas A.,Helzlsouer Kathy J.

Publisher

Elsevier BV

Subject

Ophthalmology

Reference96 articles.

1. Prednisone and prednisolone in ocular disease;Gordon;Am J Ophthalmol,1956

2. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel;Jabs;Am J Ophthalmol,2000

3. Incidence of skin cancer in 5,356 patients following organ transplantation;Lindelof;Br J Dermatol,2000

4. Incidence of skin cancer after renal transplantation in The Netherlands;Hartevelt;Transplantation,1990

5. p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status;McGregor;Oncogene,1997

Cited by 118 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignancy Risk Associated With the Use of Systemic Immunomodulatory Therapy in the Management of Noninfectious Uveitis;American Journal of Ophthalmology;2024-09

2. Formulation of Polymeric Nanoparticles Loading Baricitinib as a Topical Approach in Ocular Application;Pharmaceutics;2024-08-20

3. Long-term outcomes of noninfectious uveitis treated with systemic immunomodulatory therapy: a retrospective case series;Canadian Journal of Ophthalmology;2024-06

4. Options for systemic therapy of uveitis including alternative therapies;Expert Review of Ophthalmology;2024-03-05

5. Use of Immunosuppression and the Risk of Subsequent Overall or Cancer Mortality;Ophthalmology;2023-12